Meeder Asset Management Inc Tyme Technologies, Inc. Transaction History

Meeder Asset Management Inc

$1.48 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 11, 2022	SELL	$0.6 - $1.04 $2,466 - $4,275	-4,111 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$1.34 - $3.53 $5,508 - $14,511	4,111 New	4,111 $6,000
Q3 2019 Oct 17, 2019	SELL	$0.97 - $1.77 $1,279 - $2,334	-1,319 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$0.96 - $1.89 $675 - $1,330	704 Added 114.47%	1,319 $2,000
Q1 2019 Apr 16, 2019	SELL	$1.76 - $3.73 $1,198 - $2,540	-681 Reduced 52.55%	615 $1,000
Q4 2018 Jan 17, 2019	BUY	$2.01 - $4.21 $1,569 - $3,288	781 Added 151.65%	1,296 $5,000
Q3 2018 Nov 02, 2018	SELL	$2.18 - $3.44 $568 - $897	-261 Reduced 33.63%	515 $0
Q2 2018 Jul 24, 2018	BUY	$2.05 - $4.09 $1,590 - $3,173	776 New	776 $0

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.